Author

David M Brown

Director of Research, Retina Consultants of Houston - Cited by 69,867 - macular surgery - diabetic retinopathy - age-related macular degeneration

Biography

David M Brown  is affiliated to Heriot-Watt University. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.  His research interests reflect in his wide range of publications in various national and international journals.  
Title
Cited by
Year
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two …
CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ...The Lancet 399 (10326), 741-755, 2022202
155
2022
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double …
JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ...The Lancet 399 (10326), 729-740, 2022202
143
2022
Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders
RF Spaide, CMG Cheung, H Matsumoto, S Kishi, CJF Boon, EHC van Dijk, ...Progress in Retinal and Eye Research 86, 100973, 2022202
114
2022
Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial
DM Brown, CC Wykoff, D Boyer, JS Heier, WL Clark, A Emanuelli, ...JAMA ophthalmology 139 (9), 946-955, 2021202
78
2021
KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema
DM Brown, A Emanuelli, F Bandello, JJE Barranco, J Figueira, E Souied, ...American journal of ophthalmology 238, 157-172, 2022202
58
2022
A firmware update architecture for internet of things
B Moran, H Tschofenig, D Brown, M Meriacdraft-ietf-suit-architecture-08, 2021202
44
2021
Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28
EY Chew, TE Clemons, E Agrón, A Domalpally, TDL Keenan, S Vitale, ...JAMA ophthalmology 140 (7), 692-698, 2022202
37
2022
Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time
DM Marcus, PS Silva, D Liu, LP Aiello, A Antoszyk, M Elman, S Friedman, ...JAMA ophthalmology 140 (10), 946-954, 2022202
24
2022
Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and subretinal pigment epithelium disease in neovascular age-related macular degeneration
JP Ehlers, R Zahid, PK Kaiser, JS Heier, DM Brown, X Meng, J Reese, ...Ophthalmology Retina 5 (12), 1204-1213, 2021202
22
2021
MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid
AM Khanani, DM Brown, GJ Jaffe, CC Wykoff, E Adiguzel, R Wong, ...Ophthalmology 129 (9), 974-985, 2022202
21
2022
Tree-rings reveal two strong solar proton events in 7176 and 5259 BCE
N Brehm, M Christl, TDJ Knowles, E Casanova, RP Evershed, F Adolphi, ...Nature Communications 13 (1), 1196, 222
20
2022
Aqueous cytokine expression and higher order OCT biomarkers: assessment of the anatomic-biologic bridge in the IMAGINE DME study
JR Abraham, CC Wykoff, S Arepalli, L Lunasco, JY Hannah, M Hu, ...American journal of ophthalmology 222, 328-339, 2021202
19
2021
Visual acuity variability: comparing discrepancies between Snellen and ETDRS measurements among subjects entering prospective trials
JY Hannah, PK Kaiser, D Zamora, M Bocanegra, C Cone, DM Brown, ...Ophthalmology Retina 5 (3), 224-233, 2021202
18
2021
Intravitreal aflibercept injection vs sham as prophylaxis against conversion to exudative age-related macular degeneration in high-risk eyes: a randomized clinical trial
JS Heier, DM Brown, SP Shah, N Saroj, S Dang, NK Waheed, CC Wykoff, ...JAMA ophthalmology 139 (5), 542-547, 2021202
16
2021
Association of ultra-widefield fluorescein angiography–identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time
PS Silva, DM Marcus, D Liu, LP Aiello, A Antoszyk, M Elman, S Friedman, ...JAMA ophthalmology 140 (10), 936-945, 2022202
15
2022
Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial
MG Maguire, D Liu, SB Bressler, SM Friedman, M Melia, CR Stockdale, ...JAMA ophthalmology 139 (12), 1266-1273, 2021202
11
2021
Intravitreal nesvacumab (antiangiopoietin 2) plus aflibercept in diabetic macular edema: Phase 2 RUBY randomized trial
DM Brown, DS Boyer, K Csaky, R Vitti, L Perlee, KW Chu, F Asmus, ...Retina (Philadelphia, Pa.) 42 (6), , 2022202
11
2022
Expanded clinical spectrum of pentosan polysulfate maculopathy: a macula society collaborative study
N Jain, A Liao, SJ Garg, SN Patel, CC Wykoff, JY Hannah, NJS London, ...Ophthalmology retina 6 (3), 219-227, 2022202
11
2022
Four-year visual outcomes in the protocol w randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy
RK Maturi, AR Glassman, K Josic, CW Baker, AT Gerstenblith, LM Jampol, ...JAMA 329 (5), 376-385, 2023202
10
2023
Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy
W Fan, A Uji, M Nittala, CC Wykoff, D Brown, A Fleming, G Robertson, ...British Journal of Ophthalmology 6 (8), 1126-1131, 2022202
10
2022

Referred From: https://scholar.google.com/citations?user=9QfPsKUAAAAJ&hl=en

Cited by
Citations 69867
h-index 115
i10-index 538
Open Access Journals